This platform introduces a non-viral gene delivery system using umbilical mesenchymal stem cells (UMSCs) engineered via electroporation to carry multiple therapeutic genes. UMSCs＇ low immunogenicity and tumor-tropic properties enable targeted delivery to solid tumors, achieving both tumor suppression and immune modulation. The approach offers high safety, scalability, and off-the-shelf potential, representing a next-generation strategy for gene and cell-based cancer therapy.

We introduce a novel multi-gene engineered mesenchymal stem cell system, integrating PD-1 immune checkpoint blockade, HSV-TK suicide gene therapy, and miRNA or immunomodulatory modules. Through non-viral electroporation and transposon-based gene integration, it ensures stable, safe, and efficient delivery. Combining tumor targeting, immune activation, and therapeutic effects, it overcomes CAR-T limitations and supports scalable, off-the-shelf applications with strong clinical potential.

This platform targets hard-to-treat solid tumors using off-the-shelf UMSCs with non-viral multi-gene delivery, offering high safety, stable expression, and tumor targeting. It supports applications in regenerative medicine, biotech, immunotherapy, and precision medicine. With scalable manufacturing, global patent coverage, and strong translational value, it offers a differentiated solution for next-generation cancer gene and cell therapy.